1. The role of the BM milieu in MM progression and therapeutic resistance
   Matthew Ho et al, 2020, Clinical Lymphoma Myeloma and Leukemia CrossRef
2. Ex Vivo Models Simulating the Bone Marrow Environment and Predicting Response to Therapy in Multiple Myeloma
   Konstantinos Papadimitriou et al, 2020, Cancers CrossRef
3. Updates to the drug‐resistant mechanism of proteasome inhibitors in multiple myeloma
   Yang Bai et al, 2020, Asia‐Pac J Clin Oncol CrossRef
4. DNA Damage Response in Multiple Myeloma: The Role of the Tumor Microenvironment
   Takayuki Saitoh et al, 2021, Cancers CrossRef
5. FABP5, a Novel Immune-Related mRNA Prognostic Marker and a Target of Immunotherapy for Multiple Myeloma.
   Haipeng Jia et al, 2021, Front Med (Lausanne) CrossRef
6. Next-Generation Biomarkers in Multiple Myeloma: Understanding the Molecular Basis for Potential Use in Diagnosis and Prognosis
   Amro M. Soliman et al, 2021, IJMS CrossRef
7. Identification of the Cysteine Protease Legumain as a Potential Chronic Hypoxia-Specific Multiple Myeloma Target Gene
   Ada-Sophia Clees et al, 2022, Cells CrossRef
8. Targeting Chemokine Receptor CCR1 as a Potential Therapeutic Approach for Multiple Myeloma
   Annette Gilchrist et al, 2022, Front. Endocrinol. CrossRef
9. The serine protease matriptase inhibits migration and proliferation in multiple myeloma cells
   Ida Steiro et al, 2022, Oncotarget CrossRef
10. Identification of key genes and miRNA-mRNA regulatory networks associated with bone marrow immune microenvironment regulations in multiple myeloma by integrative bioinformatics analysis
    Niluopaer Tuerxun et al, 2022, Hematology CrossRef
11. null
    Thudzelani Takalani Austin Malise et al, 2023 CrossRef